Latest Funding Risk News

Sarytogan Graphite has launched a non-renounceable entitlement offer targeting up to $3.85 million, but only $1 million is underwritten and the issue depends on a Kazakh regulatory permit. The prospectus also flags going-concern uncertainty, substantial future project funding needs and dilution for shareholders who do not participate.

X2M Connect has lodged a prospectus for a $3.6 million non-renounceable entitlement offer, with shareholders offered discounted shares, options and bonus shares. The raise is intended to fund technology and data centre initiatives, but the offer is not underwritten and the company warns that failure to complete it would create significant uncertainty over its ability to continue as a going concern.

AXP Energy received applications for $262,214 in its 1-for-1 entitlement offer, far below the $1.2 million minimum subscription. A separate shortfall offer remains open until 3 February 2027, leaving the final capital raised unresolved.

American West Metals has converted part of its Storm resource into a maiden 12.58Mt Ore Reserve and outlined an 11-year copper mine in Nunavut. The project shows a US$118.9 million post-tax NPV at the company’s base-case prices, but still depends on funding, permitting and a further study before construction can begin.

Desane Group Holdings (ASX:DGH) is entering FY27 with a $105.9 million asset base, conservative gearing and two developments expected to drive its next phase of earnings. The challenge is converting that balance-sheet strength into recurring income while navigating construction costs, funding risk and a chairman transition.

First Lithium has secured three-year renewals for its Gouna and Faraba exploration licences in Mali, removing the stated hold-up to its maiden JORC resource. The company now faces a more familiar challenge: funding the next phase while seeking ASX re-admission.

Radiopharm Theranostics has reached final alignment with the U.S. FDA on a single pivotal Phase 3 trial for RAD101, its brain metastases imaging agent. The approximately 280-patient study is expected to begin dosing in the first half of 2027, moving the program from regulatory planning towards execution.

Percheron Therapeutics has lodged a prospectus for up to 280 million options linked to its earlier $2.3 million placement, with the securities carrying a $0.01 exercise price and expiring in April 2028. The filing raises no meaningful cash on issue, but could provide up to $2.8 million if all options are later exercised while adding a potentially dilutive layer to the capital structure.

Javelin Minerals’ board has unanimously urged shareholders to accept First Au’s all-scrip takeover, even as an independent expert concluded the offer is not fair but reasonable. The proposal values each Javelin share at 10.29 cents based on FirstAU’s latest stated price, with funding risks and a key shareholder vote still ahead.

Neurizon Therapeutics has secured A$4.3 million through a discounted placement and is seeking another A$2.0 million from eligible shareholders, while redeeming its remaining Obsidian convertible notes. The move removes current note-conversion dilution, but shifts funding risk towards equity holders ahead of a pivotal NUZ-001 trial readout.

ADX Energy has launched a discounted 2-for-5 renounceable rights issue targeting up to A$5.2 million, with proceeds aimed at Vienna Basin production work and new Austrian gas activity. The raise is only partially underwritten, while the prospectus warns that failure to complete it would create significant going-concern uncertainty.

FBR has converted its first Mantis welding robot sale into a binding A$990,000 order and secured a North American distributor. The commercial progress comes alongside A$2.073 million of quarterly operating cash burn and a reported 0.12 quarters of funding at period end.